Jeroen Kortekaas received his PhD from the University of Utrecht after completing his thesis on the Vaccine potential of iron-regulated outer membrane receptors of Neisseria meningitidis. In 2006, he moved to Wageningen Bioveterinary Research. His main responsibility at WBVR is to develop vaccines for the control of notifiable transboundary veterinary and zoonotic viral diseases. The first vaccine that was developed under his supervision can be applied for the control of Classical swine fever virus (Flaviviridae, genus Pestivirus) and enables the Differentiation between Infected and Vaccinated Animals (DIVA). After this vaccine was transferred to industry, his focus shifted to bunyaviruses. From 2007 until today, the research of his team focuses on Rift Valley fever virus (RVFV) and other members of the family Bunyaviridae. This work has resulted in a novel live-attenuated RVF vaccine that is being developed further in collaboration with industry. He is currently expanding the expertise of his research group on zoonotic arthropod-borne (arbo)viruses of the families Togaviridae and Flaviviridae in collaboration with the Universities of Wageningen, Pretoria and Hannover. Apart from his involvement in vaccine development and fundamental studies on arboviruses, he is an ad hoc member of several RVF expert panels of e.g. the World Organisation for Animal Health (Office International des Epizooties, OIE) and the Food and Agriculture Organization (FAO) of the United Nations. In November 2017, he was appointed Extraordinary Professor of Veterinary Arbovirology, affiliated with the Laboratory of Virology of Wageningen University.
Jeroen Kortekaas is co-inventor of vaccine platform technologies. Corresponding intellectual property rights were transferred from WBVR to BunyaVax B.V. He currently supports BunyaVax B.V. as Chief Scientific Officer (CSO), but does not benefit financially from these activities.